ҹɫÊÓƵ

DxDiscovery focuses on the development of medical diagnostics tests for infectious disease. Diagnostic tests are critical to making quick and accurate treatment decisions; however, for many infections there are no diagnostic tests or the tests are not reliable. Importantly, it is estimated that current diagnostic tests account for two percent of the total cost of healthcare in the United States; however, they contribute to eighty percent of medical decisions.

Renogenyx is a gene therapy biotechnology company developing therapeutics for neuromuscular conditions. The company’s mission is to change the lives of people living with muscular dystrophies through the development of safe and effective treatments.

NevadaNano develops and manufactures MEMS-based sensor modules and subsystems for a diverse array of government and commercial applications. Our products are used by system integrator partners and by system manufacturers who benefit from the unique characteristics of our sensors - namely small size, low cost, unattended operation, and the ability to detect a broad range of threats with a single, standard sensor configuration.

Strykagen is currently working on developing therapeutics for Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), Merosin deficient congenital muscular dystrophy (MDC1A) and Limb Girdle Muscular Dystrophies (LGMD).